BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:14:00 - 15:30 UK Time\n\nIn this webinar\, the EU regulatory an d Industry members of the ICH E9(R1) working group will present the new dr aft addendum for ICH E9 on estimands and sensitivity analysis. \; The addendum introduces a new framework for designing and analysing clinical t rials aligned to the trial objectives. \; \; \n\nClick here \; to view the flyer.\n\nRob Hemmings (MHRA) will present the motivation behi nd the new draft addendum\, define estimands and sensitivity analysis\, an d explain different strategies that can be used in constructing an estiman d.\n\nFrank Bretz (Novartis) will present case studies to illustrate how t he new framework can be implemented in designing clinical trials and defin ing the appropriate analysis methods.\n\nA Q&\;A session will be chaire d by Frank Pé\;tavy (EMA) and Chrissie Fletcher (Amgen).\nThis webin ar is free to attend. \;\n\nClick here \;to view the presentation slides \nTo access the recording\, please visit the Video-on-Demand Librar y. DTEND:20171030T153000Z DTSTAMP:20240328T172009Z DTSTART:20171030T140000Z LOCATION: SEQUENCE:0 SUMMARY:EFPSI/EFPIA Webinar: New draft ICH E9 addendum on Estimands and Sen sitivity Analysis UID:RFCALITEM638472432090306394 X-ALT-DESC;FMTTYPE=text/html:
14:00 - 15:30 UK Time
\n
\nIn this webinar\, the EU regulatory and Industry members of the
ICH E9(R1) working group will present the new draft addendum for ICH E9 o
n estimands and sensitivity analysis. \; The addendum introduces a new
framework for designing and analysing clinical trials aligned to the tria
l objectives. \; \;
\n
\nClick here \;to view
the flyer.
\n
\nRob Hemmings (MHRA) will prese
nt the motivation behind the new draft addendum\, define estimands and sen
sitivity analysis\, and explain different strategies that can be used in c
onstructing an estimand.
\n
\nFrank Bretz (Novartis) will present case studies to illustrate how the new framework can be
implemented in designing clinical trials and defining the appropriate ana
lysis methods.
\n
\nA Q&\;A session will be chaired by
This webinar is free to attend. \;
\n
\n
Click here \;to view the presentation slides